Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole

Area of Science:

• Oncology
• Pharmacology
• Infectious Diseases

Background:

• Venetoclax is an effective BCL-2 inhibitor for certain cancers.
• Coadministration with voriconazole, a potent azole antifungal, necessitates a significant 75% dose reduction of venetoclax due to potential drug-drug interactions.
• The clinical impact of this interaction on patient outcomes, particularly hematologic toxicity, requires further investigation.

Purpose of the Study:

• To evaluate the impact of voriconazole use on hematologic outcomes in patients treated with venetoclax.
• To explore factors contributing to breakthrough invasive fungal infections in patients receiving venetoclax.

Main Methods:

• Retrospective analysis of a 10-year historical cohort of patients treated with venetoclax.
• Comparison of hematologic outcomes between patients who received voriconazole prophylaxis and those who did not.
• Review of factors associated with breakthrough invasive fungal infections.

Main Results:

• No significant difference in hematologic outcomes was observed between patients receiving venetoclax with or without voriconazole prophylaxis.
• Subtherapeutic levels of voriconazole were noted in some cases.
• Prior triazole exposure was identified as a potential risk factor for breakthrough invasive fungal infections.

Conclusions:

• The recommended venetoclax dose reduction with voriconazole may not be solely driven by hematologic toxicity concerns.
• Factors such as subtherapeutic antifungal levels and prior triazole exposure history are critical in managing breakthrough invasive fungal infections.
• Further prospective studies are warranted to fully elucidate the pharmacokinetics and clinical implications of venetoclax-voriconazole coadministration.